Drugs for treating Parkinson disease.

Nursing 20120701

Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.

JAMA 20120606

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

European journal of neurology 20120601

Finasteride attenuates pathological gambling in patients with Parkinson disease.

Journal of clinical psychopharmacology 20120601

Microbial β-glycosylation of entacapone by Cunninghamella echinulata ATCC 9245.

Journal of bioscience and bioengineering 20120501

The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.

European journal of clinical pharmacology 20120301

Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.

Expert review of neurotherapeutics 20120201

Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.

Clinical neuropharmacology 20120101

A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.

Clinical neuropharmacology 20120101

Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.

Bioorganic & medicinal chemistry 20111215

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

European journal of neurology 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.

The International journal of neuroscience 20111101

Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.

Drug metabolism and disposition: the biological fate of chemicals 20111101

Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.

Hiroshima journal of medical sciences 20110901

A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.

Parkinsonism & related disorders 20110801

Species independence in brain tissue binding using brain homogenates.

Drug metabolism and disposition: the biological fate of chemicals 20110701

Entacapone promotes cAMP-dependent colonic Cl(-) secretion in rats.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20110701

Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

Naunyn-Schmiedeberg's archives of pharmacology 20110601

Role of catechol-O-methyltransferase in the disposition of luteolin in rats.

Drug metabolism and disposition: the biological fate of chemicals 20110401

In-line reaction monitoring of entacapone synthesis by Raman spectroscopy and multivariate analysis.

Journal of pharmaceutical and biomedical analysis 20110325

Development of characterization methods for entacapone in a pharmaceutical bulk.

Journal of pharmaceutical and biomedical analysis 20110325

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.

European journal of neurology 20110301

Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.

Journal of pharmaceutical and biomedical analysis 20110220

Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.

Annals of neurology 20110201

Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.

Journal of clinical pharmacology 20110101

The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.

CNS drugs 20110101

Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.

Clinical neuropharmacology 20110101

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

Annals of neurology 20110101

Identification and categorization of liver toxicity markers induced by a related pair of drugs.

International journal of molecular sciences 20110101

A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

CNS neuroscience & therapeutics 20101201

A predictive ligand-based Bayesian model for human drug-induced liver injury.

Drug metabolism and disposition: the biological fate of chemicals 20101201

Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.

Parkinsonism & related disorders 20101201

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

International journal of clinical pharmacology and therapeutics 20101101

Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.

Nature reviews. Neurology 20101101

Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20101001

Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957.

Nuclear medicine and biology 20101001

LC determination of entacapone in tablets: in vitro dissolution studies.

Journal of chromatographic science 20101001

Entacapone: prostate cancer?

Prescrire international 20101001

Isolated delusional syndrome in Parkinson's Disease.

Parkinsonism & related disorders 20100901

Entacapone.

Expert opinion on drug metabolism & toxicology 20100801

Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.

Current medical research and opinion 20100701

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Annals of neurology 20100701

Continuous dopaminergic therapy in Parkinson disease: time to stride back?

Annals of neurology 20100701

Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.

The Journal of biological chemistry 20100514

Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

Journal of medicinal chemistry 20100422

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Journal of neural transmission (Vienna, Austria : 1996) 20100301

The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.

Movement disorders : official journal of the Movement Disorder Society 20100215

Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.

Brain research 20100114

Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.

Toxicological sciences : an official journal of the Society of Toxicology 20100101

Mirtazapine-associated urinary retention.

The Journal of neuropsychiatry and clinical neurosciences 20100101

Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Clinical drug investigation 20100101

Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.

International review of neurobiology 20100101

LC/MS/MS study for identification of entacapone degradation product obtained by photodegradation kinetics.

Journal of AOAC International 20100101

Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.

Movement disorders : official journal of the Movement Disorder Society 20091215

Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.

European journal of neurology 20091201

Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.

Movement disorders : official journal of the Movement Disorder Society 20091115

Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

Journal of neural transmission (Vienna, Austria : 1996) 20091001

Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.

Movement disorders : official journal of the Movement Disorder Society 20090715

Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.

Parkinsonism & related disorders 20090701

Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.

PLoS computational biology 20090701

Levodopa/carbidopa/entacapone in Parkinson's disease.

Expert review of neurotherapeutics 20090701

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

European journal of clinical pharmacology 20090501

Validation of the freezing of gait questionnaire in patients with Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20090415

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20090315

Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.

Neurological research 20090201

Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.

European journal of neurology 20090201

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Movement disorders : official journal of the Movement Disorder Society 20090115

Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.

European neurology 20090101

The liver toxicity biomarker study: phase I design and preliminary results.

Toxicologic pathology 20090101

Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation.

Journal of AOAC International 20090101

Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.

Clinical drug investigation 20090101

Establishing the probable mechanism of L-DOPA in Alzheimer's disease management.

Acta poloniae pharmaceutica 20090101

Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.

Journal of the neurological sciences 20081215

Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.

Neurobiology of disease 20081201

Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .

Current medical research and opinion 20081101

[Treatment of Parkinson's disease at present and in the future].

Rinsho shinkeigaku = Clinical neurology 20081101

Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20080730

Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.

European journal of neurology 20080701

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20080601

Homocysteine in restless legs syndrome.

Sleep medicine 20080501

The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.

Psychopharmacology 20080401

Long-term retention rate of entacapone in the treatment of Parkinson's disease.

European journal of neurology 20080401

On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.

Neuropharmacology 20080401

Bimodal administration of entacapone in Parkinson's disease patients improves motor control.

European journal of neurology 20080301

[Isolated pulmonary hypertension and pergolide].

Revue neurologique 20080301

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.

Clinical neuropharmacology 20080101

[Entocapone-related lymphocytic colitis].

Gastroenterologie clinique et biologique 20080101

Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.

CNS neuroscience & therapeutics 20080101

Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.

Clinical neuropharmacology 20080101

The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.

Clinical neuropharmacology 20080101

Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.

Parkinsonism & related disorders 20071201

The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.

Experimental neurology 20071201

Parkinson disease: an incremental challenge.

South Dakota medicine : the journal of the South Dakota State Medical Association 20071201

Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function.

Journal of pharmaceutical sciences 20071101

Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.

The Annals of pharmacotherapy 20071101

Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.

Movement disorders : official journal of the Movement Disorder Society 20070815

[Neuromuscular disorders due to adverse effects of antiparkinson agents].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810

Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.

Movement disorders : official journal of the Movement Disorder Society 20070730

Entacapone improves complex movement performance in patients with Parkinson's disease.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20070501

Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.

Chemico-biological interactions 20070501

Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?

Neurology 20070424

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

Neurology 20070424

Current pharmacotherapeutic treatment options in Parkinson's disease.

Disease-a-month : DM 20070401

Does the preferred orientation of crystallites in tablets affect the intrinsic dissolution?

Journal of pharmaceutical and biomedical analysis 20070312

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.

European journal of neurology 20070301

Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20070101

Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.

Movement disorders : official journal of the Movement Disorder Society 20070101

Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20070101

The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.

European neurology 20070101

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.

Clinical neuropharmacology 20070101

Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.

Movement disorders : official journal of the Movement Disorder Society 20061201

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20061001

Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).

Acta neurologica Scandinavica 20060901

Long-term care of Parkinson's disease. Strategies for managing 'wearing off' symptom re-emergence and dyskinesias.

Geriatrics 20060901

Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

Journal of the American Medical Directors Association 20060901

The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.

Expert opinion on pharmacotherapy 20060701

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

Neurology 20060627

Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.

Movement disorders : official journal of the Movement Disorder Society 20060501

Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.

Movement disorders : official journal of the Movement Disorder Society 20060301

Efficacy and safety of high-dose cabergoline in Parkinson's disease.

Acta neurologica Scandinavica 20060101

Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.

Journal of motor behavior 20060101

Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

Clinical neuropharmacology 20060101

Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.

Clinical neuropharmacology 20060101

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Clinical neuropharmacology 20060101

Synthesis and biological evaluation of a novel series of 'ortho-nitrated' inhibitors of catechol-O-methyltransferase.

Journal of medicinal chemistry 20051215

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

Neurology 20051213

Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.

Journal of mass spectrometry : JMS 20051201

High-performance liquid chromatography method for the quantification of entacapone in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050905

The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

Journal of neural transmission (Vienna, Austria : 1996) 20050901

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

Parkinsonism & related disorders 20050901

Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.

Drug metabolism and disposition: the biological fate of chemicals 20050701

Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases.

Analytical biochemistry 20050601

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

Parkinsonism & related disorders 20050601

Entacapone in the treatment of Parkinson's disease.

The Lancet. Neurology 20050601

Prediction of genotoxicity of chemical compounds by statistical learning methods.

Chemical research in toxicology 20050601

[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

Neurologia (Barcelona, Spain) 20050501

The effect of entacapone on homocysteine levels in Parkinson disease.

Neurology 20050426

UDP-glucuronosyltransferases and clinical drug-drug interactions.

Pharmacology & therapeutics 20050401

The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050401

Novel pharmacological strategies for motor complications in Parkinson's disease.

Expert opinion on investigational drugs 20050401

'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease.

Neurology 20050308

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

Movement disorders : official journal of the Movement Disorder Society 20050301

Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.

Experimental neurology 20050301

Rasagiline for motor complications in Parkinson's disease.

Lancet (London, England) 20050301

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Lancet (London, England) 20050301

Improving quality of life in early Parkinson's.

Health news (Waltham, Mass.) 20050201

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

Movement disorders : official journal of the Movement Disorder Society 20050101

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Acta neurologica Scandinavica 20050101

Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.

Movement disorders : official journal of the Movement Disorder Society 20050101

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.

Clinical neuropharmacology 20050101

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.

European neurology 20050101

Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase.

Journal of medicinal chemistry 20041202

Assessment of catechol induction and glucuronidation in rat liver microsomes.

Drug metabolism and disposition: the biological fate of chemicals 20041201

Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.

Naunyn-Schmiedeberg's archives of pharmacology 20041101

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

The Cochrane database of systematic reviews 20041018

Clinical advantages of COMT inhibition with entacapone - a review.

Journal of neural transmission (Vienna, Austria : 1996) 20041001

Extraneuronal enzymatic degradation of myocardial interstitial norepinephrine in the ischemic region.

Cardiovascular research 20041001

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Archives of neurology 20041001

Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.

Movement disorders : official journal of the Movement Disorder Society 20040901

Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.

European journal of neurology 20040901

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.

Journal of neural transmission (Vienna, Austria : 1996) 20040801

Role of entacapone in later Parkinson's disease not yet established.

Journal of neurology, neurosurgery, and psychiatry 20040701

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

Expert review of neurotherapeutics 20040701

Bullous skin eruption associated with entacapone.

International journal of dermatology 20040601

Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20040601

Stalevo for Parkinson's disease.

The Medical letter on drugs and therapeutics 20040510

In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle.

Autonomic neuroscience : basic & clinical 20040430

[Treatment in Parkinson disease].

Orvosi hetilap 20040411

An active and water-soluble truncation mutant of the human UDP-glucuronosyltransferase 1A9.

Molecular pharmacology 20040401

Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.

Neuropharmacology 20040301

Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.

Journal of neural transmission (Vienna, Austria : 1996) 20040201

The role of COMT inhibition in the treatment of Parkinson's disease.

Neurology 20040113

Safety and tolerability of COMT inhibitors.

Neurology 20040113

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.

Neurology 20040113

Continuous dopaminergic stimulation in early and advanced Parkinson's disease.

Neurology 20040113

Levodopa/carbidopa/entacapone (Stalevo).

Neurology 20040113

The value of post-marketing medication surveys in Parkinson's disease.

Current medical research and opinion 20040101

Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.

Current medical research and opinion 20040101

[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20040101

Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease.

Clinical neuropharmacology 20040101

Entacapone protects from angiotensin II-induced inflammation and renal injury.

Journal of hypertension 20031201

The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20031001

Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20031001

Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.

Progress in neuro-psychopharmacology & biological psychiatry 20030901

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Journal of neurology, neurosurgery, and psychiatry 20030801

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20030801

An artist's view of drug-induced hallucinosis.

Movement disorders : official journal of the Movement Disorder Society 20030701

The economic evaluation of pharmacotherapies for Parkinson's disease.

Parkinsonism & related disorders 20030601

Absorption rate limit considerations for oral phosphate prodrugs.

Pharmaceutical research 20030601

[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].

MMW Fortschritte der Medizin 20030526

Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.

Movement disorders : official journal of the Movement Disorder Society 20030501

Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.

Expert opinion on drug safety 20030501

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.

European journal of neurology 20030301

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.

Journal of neural transmission (Vienna, Austria : 1996) 20030301

Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.

The Journal of pharmacology and experimental therapeutics 20030201

Excessive daytime sleepiness and 'sleep attacks' induced by entacapone.

Fundamental & clinical pharmacology 20030201

Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.

Fundamental & clinical pharmacology 20030201

Position of COMT inhibition in the treatment of Parkinson's disease.

Advances in neurology 20030101

Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.

Parkinsonism & related disorders 20030101

Entacapone/levodopa/carbidopa combination tablet: Stalevo.

Drugs in R&D 20030101

Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.

Journal of neural transmission (Vienna, Austria : 1996) 20021101

Entacapone-induced hepatotoxicity and hepatic dysfunction.

Movement disorders : official journal of the Movement Disorder Society 20021101

Effects of entacapone and tolcapone on mitochondrial membrane potential.

European journal of pharmacology 20021018

Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

British journal of clinical pharmacology 20021001

[The usefulness of dopaminergic drugs in traumatic brain injury].

Revista de neurologia 20020801

[Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome].

Der Nervenarzt 20020801

Catechol-o-methyltransferase and blood pressure in humans.

Circulation 20020723

Comparison of electrospray, atmospheric pressure chemical ionization, and atmospheric pressure photoionization in the identification of apomorphine, dobutamine, and entacapone phase II metabolites in biological samples.

Analytical chemistry 20020715

Entacapone in the management of Parkinson's disease.

Expert opinion on pharmacotherapy 20020701

Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20020701

Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.

Pharmacology & toxicology 20020601

The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.

Parkinsonism & related disorders 20020601

Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.

British journal of clinical pharmacology 20020501

Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.

Journal of neural transmission (Vienna, Austria : 1996) 20020501

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Acta neurologica Scandinavica 20020401

Design and synthesis of a novel L-dopa-entacapone codrug.

Journal of medicinal chemistry 20020314

Entacapone in restless legs syndrome.

Movement disorders : official journal of the Movement Disorder Society 20020301

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.

Neurology 20020226

Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.

Journal of medicinal chemistry 20020131

Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.

Journal of neural transmission (Vienna, Austria : 1996) 20020101

Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

PharmacoEconomics 20020101

COMT inhibitors: management of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20020101

Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.

The Journal of pharmacy and pharmacology 20011101

Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats.

Toxicological sciences : an official journal of the Society of Toxicology 20010901

Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Biomedical sciences and applications 20010815

L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.

Psychopharmacology 20010801

Current advances in Parkinson's disease.

Trends in neurosciences 20010701

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Clinical therapeutics 20010601

[Parkinson disease. Value of COMT inhibitors is verified].

MMW Fortschritte der Medizin 20010503

D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.

Kidney international 20010501

Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.

Synapse (New York, N.Y.) 20010401

[Parkinson's disease].

Presse medicale (Paris, France : 1983) 20010303

[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].

Neurologia (Barcelona, Spain) 20010201

Possible applications for dopaminergic agents following traumatic brain injury: part 2.

The Journal of head trauma rehabilitation 20010201

Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.

European neurology 20010101

Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.

Journal of neural transmission (Vienna, Austria : 1996) 20010101

The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.

Clinical neuropharmacology 20010101

Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.

European journal of clinical pharmacology 20010101

The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.

Journal of neural transmission (Vienna, Austria : 1996) 20010101

Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.

Seminars in neurology 20010101

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.

Clinical neuropharmacology 20010101

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

European neurology 20010101

Twelve-month safety of entacapone in patients with Parkinson's disease.

European journal of neurology 20010101

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.

Clinical neuropharmacology 20010101

Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20010101

COMT inhibition and safety.

Functional neurology 20010101

[Dopaminergic agonists in the treatment of Parkinson's disease].

Revue medicale de Bruxelles 20001201

Entacapone.

The Annals of pharmacotherapy 20000901

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Drugs 20000601

Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.

The European journal of neuroscience 20000301

Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.

Biochemistry 19950404

Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.

European journal of pharmacology 19950214